<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><description>佰傲谷致力于打造一个垂直于生物制品领域的第三方平台。为生物制药企业提供品牌推广、技术咨询、项目交易、企业合作、人才培养等服务。为生物制药行业从业人员提供沟通交流、会议培训、工作求职、个人展示平台。</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 06 Jun 2021 11:03:47 +0800</pubDate><image><url>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</url><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>靶点药讯63|泽璟制药JAK抑制剂启动3期临床、中国首个儿童专属器官移植免疫抑制剂获批上市</title><link>https://mp.weixin.qq.com/s/DNJtVnCSiApner0GB7ZoTQ</link><description></description><content:encoded><![CDATA[靶点药讯63|泽璟制药JAK抑制剂启动3期临床、中国首个儿童专属器官移植免疫抑制剂获批上市]]></content:encoded><pubDate>Sun, 06 Jun 2021 09:34:29 +0800</pubDate></item><item><title>浅谈新法规下药学变更管理的思路及产品稳定性研究</title><link>https://mp.weixin.qq.com/s/v3r923P_0vQ5LPIifqb_zw</link><description></description><content:encoded><![CDATA[浅谈新法规下药学变更管理的思路及产品稳定性研究]]></content:encoded><pubDate>Sun, 06 Jun 2021 09:34:29 +0800</pubDate></item><item><title>征祥医药完成2亿元A+轮融资</title><link>https://mp.weixin.qq.com/s/va3FBwTvvXS9fXBGNLHOjA</link><description></description><content:encoded><![CDATA[征祥医药完成2亿元A+轮融资]]></content:encoded><pubDate>Sun, 06 Jun 2021 09:34:29 +0800</pubDate></item><item><title>诺华销售王IL-17单抗--Cosentyx再获FDA批准新适应症</title><link>https://mp.weixin.qq.com/s/nFAObWJAGOCy6ftO19WeGg</link><description></description><content:encoded><![CDATA[诺华销售王IL-17单抗--Cosentyx再获FDA批准新适应症]]></content:encoded><pubDate>Sat, 05 Jun 2021 08:55:23 +0800</pubDate></item><item><title>行业精英齐聚：多肽药物开发研修班精彩内容抢先看～</title><link>https://mp.weixin.qq.com/s/85pSx2BZReiKbcC_ov3WFg</link><description></description><content:encoded><![CDATA[行业精英齐聚：多肽药物开发研修班精彩内容抢先看～]]></content:encoded><pubDate>Sat, 05 Jun 2021 08:55:23 +0800</pubDate></item><item><title>Self Renew专栏｜早期SARS-CoV-2抗体通过肺泡巨噬细胞促进炎症反应</title><link>https://mp.weixin.qq.com/s/piMARGfnjjADnjW56OI_Ww</link><description></description><content:encoded><![CDATA[Self Renew专栏｜早期SARS-CoV-2抗体通过肺泡巨噬细胞促进炎症反应]]></content:encoded><pubDate>Fri, 04 Jun 2021 10:55:18 +0800</pubDate></item><item><title>羊驼纳米抗体建库筛选技术基本流程</title><link>https://mp.weixin.qq.com/s/RjmNkvchrOTsfdDnXkDUew</link><description></description><content:encoded><![CDATA[羊驼纳米抗体建库筛选技术基本流程]]></content:encoded><pubDate>Fri, 04 Jun 2021 10:55:18 +0800</pubDate></item><item><title>治疗性癌症疫苗</title><link>https://mp.weixin.qq.com/s/rBt7aJ4BNiwEkJkeqxEr4g</link><description></description><content:encoded><![CDATA[治疗性癌症疫苗]]></content:encoded><pubDate>Fri, 04 Jun 2021 10:55:18 +0800</pubDate></item><item><title>斯微生物宣布完成12亿元新一轮融资</title><link>https://mp.weixin.qq.com/s/0sS6VKZ7Owj1wWQ6Wk_JQg</link><description></description><content:encoded><![CDATA[斯微生物宣布完成12亿元新一轮融资]]></content:encoded><pubDate>Wed, 02 Jun 2021 22:09:36 +0800</pubDate></item><item><title>极目生物祝贺Clearside公司XIPERE™在美国新药上市申请获得受理</title><link>https://mp.weixin.qq.com/s/IkJR4onrSdD-ecrkVC-4Tw</link><description></description><content:encoded><![CDATA[极目生物祝贺Clearside公司XIPERE™在美国新药上市申请获得受理]]></content:encoded><pubDate>Wed, 02 Jun 2021 22:09:36 +0800</pubDate></item><item><title>入局mRNA领域，艾美疫苗控股丽凡达生物</title><link>https://mp.weixin.qq.com/s/dz6DT-YZiwQ-Hb86u6LhEA</link><description></description><content:encoded><![CDATA[入局mRNA领域，艾美疫苗控股丽凡达生物]]></content:encoded><pubDate>Wed, 02 Jun 2021 22:09:36 +0800</pubDate></item><item><title>国内企业License-in的重磅药</title><link>https://mp.weixin.qq.com/s/GWhdoJ07CSWwwVRw2W6I9A</link><description></description><content:encoded><![CDATA[国内企业License-in的重磅药]]></content:encoded><pubDate>Wed, 02 Jun 2021 22:09:36 +0800</pubDate></item><item><title>诚邀参与 |  2021东方美谷生命健康发展论坛暨上海 CDMO 产业投资发展大会</title><link>https://mp.weixin.qq.com/s/A_Ie2kRpK_xXTgOYimn6rQ</link><description></description><content:encoded><![CDATA[诚邀参与 |  2021东方美谷生命健康发展论坛暨上海 CDMO 产业投资发展大会]]></content:encoded><pubDate>Wed, 02 Jun 2021 11:57:46 +0800</pubDate></item><item><title>CAR-T发展历史及展望</title><link>https://mp.weixin.qq.com/s/fLW44tTdVYziFkvi4_oX2g</link><description></description><content:encoded><![CDATA[CAR-T发展历史及展望]]></content:encoded><pubDate>Wed, 02 Jun 2021 11:57:46 +0800</pubDate></item><item><title>12.5亿美元：安进引进协和发酵麒麟OX40抗体</title><link>https://mp.weixin.qq.com/s/ce8QNxrpM9ORcwMHIEIxOA</link><description></description><content:encoded><![CDATA[12.5亿美元：安进引进协和发酵麒麟OX40抗体]]></content:encoded><pubDate>Wed, 02 Jun 2021 11:57:46 +0800</pubDate></item><item><title>靶向蛋白复合体的药物研发机遇与挑战</title><link>https://mp.weixin.qq.com/s/Hx_pqdFHFZkciLAy6pYQKA</link><description></description><content:encoded><![CDATA[靶向蛋白复合体的药物研发机遇与挑战]]></content:encoded><pubDate>Wed, 02 Jun 2021 11:57:46 +0800</pubDate></item><item><title>新型药物靶标集锦</title><link>https://mp.weixin.qq.com/s/ZpQNTcwa5yvFq3k06UYx4Q</link><description></description><content:encoded><![CDATA[新型药物靶标集锦]]></content:encoded><pubDate>Wed, 02 Jun 2021 11:57:46 +0800</pubDate></item><item><title>AI如何助力人类制造COVID-19疫苗</title><link>https://mp.weixin.qq.com/s/z7oQ2EKY2Ht8XMcqa4siHQ</link><description></description><content:encoded><![CDATA[AI如何助力人类制造COVID-19疫苗]]></content:encoded><pubDate>Tue, 01 Jun 2021 12:23:09 +0800</pubDate></item><item><title>KRAS G12C的过度竞争：重复PD-1的故事</title><link>https://mp.weixin.qq.com/s/tJHckndq9d9VPPoVLC4afA</link><description></description><content:encoded><![CDATA[KRAS G12C的过度竞争：重复PD-1的故事]]></content:encoded><pubDate>Tue, 01 Jun 2021 12:23:09 +0800</pubDate></item><item><title>坐实肝风险，奥贝胆酸新添黑框警告</title><link>https://mp.weixin.qq.com/s/Dec_N8D2kdEhormhkYGpJg</link><description></description><content:encoded><![CDATA[坐实肝风险，奥贝胆酸新添黑框警告]]></content:encoded><pubDate>Tue, 01 Jun 2021 12:23:09 +0800</pubDate></item></channel></rss>